Recursion Pharmaceuticals is a biotechnology business based in the US. Recursion Pharmaceuticals shares (RXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Recursion Pharmaceuticals employs 550 staff and has a trailing 12-month revenue of around $50 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $7.97 |
|---|---|
| 52-week range | $4.54 - $16.75 |
| 50-day moving average | $10.33 |
| 200-day moving average | $8.40 |
| Wall St. target price | $15.71 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.41 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.97 from 2023-09-21
| 1 week (2023-09-15) | -7.00% |
|---|---|
| 1 month (2023-08-22) | -12.22% |
| 3 months (2023-06-22) | 3.37% |
| 6 months (2023-03-22) | 14.18% |
| 1 year (2022-09-22) | -25.58% |
|---|---|
| 2 years (2021-09-22) | -67.34% |
| 3 years (2020-09-18) | N/A |
| 5 years (2018-09-18) | N/A |
| Revenue TTM | $50 million |
|---|---|
| Gross profit TTM | $-164,128,000 |
| Return on assets TTM | -25.83% |
| Return on equity TTM | -57.36% |
| Profit margin | 0% |
| Book value | $2.27 |
| Market Capitalization | $1.9 billion |
TTM: trailing 12 months
We're not expecting Recursion Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Recursion Pharmaceuticals's shares have ranged in value from as little as $4.54 up to $16.745. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recursion Pharmaceuticals's is -0.1656. This would suggest that Recursion Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Recursion Pharmaceuticals has bucked the trend.
To put Recursion Pharmaceuticals's beta into context you can compare it against those of similar companies.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc. ; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.